CohBar, Inc. Announces Changes to Its Board of Directors and R&D Leadership
December 17, 2021 at 09:00 am EST
CohBar, Inc. announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBars founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the companys Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other disciplines, working with CohBars leadership to advance its pipeline and Mito+ platform. In addition, Ken Cundy, Ph.D. has resigned from his position as Chief Scientific Officer, effective March 31, 2022, in order to explore other opportunities. The company announced the appointment of Kent Grindstaff, Ph.D., as CohBars Senior Vice President of Research, effective January 4, 2022. Dr. Grindstaff is well-versed in the companys science and programs as he previously served for six years as the VP, Biology at CohBar. Dr. Grindstaff rejoins the company from BioAge Labs, where he was the Senior Vice President, Discovery Research. Earlier in his career, Dr. Grindstaff was Vice President, Global Operations at Solvo Biotechnology USA and Principal Investigator at XenoPort, Inc.Dr. Grindstaff holds a B.A. in Biology from Knox College, received his Ph.D. in Molecular Cell Biology and Biochemistry from Washington University in St. Louis and completed his post-doctoral fellowship in the Department of Molecular and Cellular Physiology at Stanford University.